We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Guardant Health (GH - Free Report) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Guardant Health metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Development services and other' will reach $11.74 million. The estimate suggests a change of -1.4% year over year.
The consensus among analysts is that 'Revenue- Precision oncology testing' will reach $150.45 million. The estimate indicates a change of +20.1% from the prior-year quarter.
Analysts' assessment points toward 'Total tests performed (clinical & biopharmaceutical customers)' reaching 57,358. Compared to the current estimate, the company reported 43,500 in the same quarter of the previous year.
Shares of Guardant Health have demonstrated returns of +10.8% over the past month compared to the Zacks S&P 500 composite's -6.7% change. With a Zacks Rank #3 (Hold), GH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
Wall Street analysts forecast that Guardant Health (GH - Free Report) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Guardant Health metrics that are commonly tracked and forecasted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Development services and other' will reach $11.74 million. The estimate suggests a change of -1.4% year over year.
The consensus among analysts is that 'Revenue- Precision oncology testing' will reach $150.45 million. The estimate indicates a change of +20.1% from the prior-year quarter.
Analysts' assessment points toward 'Total tests performed (clinical & biopharmaceutical customers)' reaching 57,358. Compared to the current estimate, the company reported 43,500 in the same quarter of the previous year.
View all Key Company Metrics for Guardant Health here>>>
Shares of Guardant Health have demonstrated returns of +10.8% over the past month compared to the Zacks S&P 500 composite's -6.7% change. With a Zacks Rank #3 (Hold), GH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>